Best Life Sciences Companies in Finland
The 219 best Life Sciences companies in Finland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Faron Pharmaceuticals.
Finland's Life Sciences sector has 219 companies on our radar, carrying $915M in total disclosed funding and zero unicorns — which tells you something real about where this ecosystem sits right now. Faron Pharmaceuticals leads the field with $160M raised, a figure that dwarfs the next tier: TILT Biotherapeutics at $29M, Valo Therapeutics at $25M, Aiforia at $23M. The global life sciences market is tracking toward a 10.2% CAGR, and that tailwind matters for Finnish founders operating in drug development, oncology platforms, and quantum-aided therapeutics. Aging populations are the demand engine here. No hype needed.
So what does the funding map actually tell you? It's concentrated. Faron alone accounts for roughly 17% of all disclosed capital in the directory, and the drop-off after the top six names is steep. Investors anchoring this market — Europa, EIC Fund, Tesi, Innovestor, Business Finland — skew toward early-stage bets, which explains the spread of smaller raises. I'd watch the pipeline closely: a wave of life sciences IPO activity globally signals that exit windows are reopening, and Finnish companies with validated clinical data are positioned to move when conditions tighten.
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Finland
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Faron Pharmaceuticals Clinical-stage developing immunotherapy for cancer, aorta aneurysm & ARDS | $160M | 14 mo ago | 40 | 2007 | Markku Jalkanen Founder & CEO | WordPress Block EditorWordPressMySQL+18 | 275 patents Targeted immunotherapy using anti‑Clever‑1 antibodies and related biomarkers for cancer | — |
| 2 | Biotie Commercial Stage biotech company developing drugs against CNS disease. | $150M | 131 mo ago | 27 | 1998 | Jari Saarinen CEO | — | — | — |
| 3 | Nanoform Provider of a platform for the development of nano particles | $48M | 28 mo ago | 158 | 2008 | Jouko Yliruusi Co-Founder | WordPressApple iCloud MailMicrosoft 365+22 | — | — |
| 4 | Inion Manufacturing biodegradable and bioactive implants for Orthopaedic and dental applications | $34M | 250 mo ago | 38 | 1999 | — | WordPress Block EditorWordPressMySQL+17 | 82 patents Spinal graft suspension systems and surgical implantation tools for orthopedic procedures. | — |
| 5 | Nexstim Provider of noninvasive brain stimulation for rehabilitating stroke patients | $30M | 100 mo ago | 37 | 2000 | Mikko Karvinen Chief Executive Officer | TYPO3 CMSPHPSalesforce+12 | 135 patents Advanced navigated transcranial magnetic stimulation devices and therapeutic pulse protocols. | — |
| 6 | TILT Biotherapeutics Developer of oncolytic viral immunotherapies for solid tumors | $29M | 13 mo ago | 21 | 2013 | Akseli Hemminki Chief Executive Officer | WordPressMySQLPHP+10 | 73 patents Oncolytic viral therapies and adoptive cell immunotherapies targeting cancer and microbiome. | — |
| 7 | Mendor Blood glucose monitoring device | $28M | 122 mo ago | 16 | 2006 | — | — | 31 patents Blood glucose monitoring devices and calibrated test‑strip cartridge technologies | — |
| 8 | Desentum Developing novel types of allergen immunotherapy products (allergy vaccines) | $27M | 27 mo ago | 6 | 2011 | Janne Janis Co-Founder | WordPressMySQLPHP+18 | 40 patents Thermosensitive hydrogel drug delivery systems and engineered hypoallergenic peanut protein therapeutics. | 3 job openings |
| 9 | Blueprint Genetics Provider of genetic diagnostics and clinical interpretation for hereditary diseases | $26M | 107 mo ago | 143 | 2012 | Tero Pekka Alastalo Co-Founder | Cart FunctionalityWordPressApple iCloud Mail+26 | — | 1 launch |
| 10 | Forendo Pharma Provider of small molecule based therapeutics for reproductive health | $26M | 83 mo ago | 23 | 2013 | — | — | 87 patents Selective 17β‑hydroxysteroid dehydrogenase type 1 inhibitor compounds for hormone‑related therapies | — |
| 11 | Valo Therapeutics Developer of immunotherapies for cancer and infectious disease | $25M | 15 mo ago | 20 | 2016 | — | DrupalPHPNginx+11 | 61 patents Oncolytic viral vector platforms for cancer immunotherapy and vaccine development | — |
| 12 | Nightingale Provider of a metabolomic technology platform for blood analysis and research | $23M | 65 mo ago | 64 | 2013 | — | VimeoApache HTTP ServerAmazon Web Services+14 | — | — |
| 13 | Aiforia Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas | $23M | 6 mo ago | 3 | 2014 | Jukka Tapaninen CEO | HubSpot CMS HubApple iCloud MailGoogle Workspace+26 | — | — |
| 14 | Algorithmiq Developer of quantum algorithms for chemistry and life science applications | $20M | 1 mo ago | 24 | 2020 | Sabrina Maniscalco Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+16 | 26 patents Quantum algorithms for expectation estimation, noise mitigation, and fermionic encoding in quantum computing | 1 expansion |
| 15 | Aplagon Heparin peptidoglycan mimetics for treating complications of vascular intervention-related blood vessel… | $19M | 16 mo ago | 1 | 2009 | Riitta Lassila Co-Founder | — | 32 patents Heparin‑protein conjugate antithrombotic drugs for thrombocytopenia treatment | — |
| 16 | Hormos Medical Research and development of products to treat endocrine disorders associated with aging. | $17M | 297 mo ago | — | 1997 | — | — | 305 patents Selective estrogen receptor modulators and oral dosage formulations for urogenital therapies | — |
| 17 | Mobidiag In vitro diagnostics for infectious diseases | $16M | 77 mo ago | 128 | 2000 | — | — | 100 patents Rapid molecular diagnostic kits for detecting pathogenic bacteria and toxins via nucleic acid amplification | — |
| 18 | DelSiTech Developer of silica-based drugs to treat various diseases | $13M | 34 mo ago | 40 | 2001 | — | WordPressMySQLPHP+20 | 97 patents Silica‑based hydrogel drug delivery systems and injectable depot formulations | — |
| 19 | HVR Cardio Provider of mitral valve leakage therapeutics development services | $11M | 41 mo ago | — | 2002 | Olli Keranen Founder & CSO | — | 75 patents Cardiac valve annuloplasty devices and catheter-based implantation systems | — |
| 20 | CurifyLabs Provider of digital 3D printing solutions for personalized medicine | $11M | 12 mo ago | 16 | 2021 | Niklas Topelius Co-Founder | HubSpot CMS HubFacebook LoginLinkedin Sign-in+20 | 12 patents Advanced pharmaceutical formulation and dispensing systems, including blade‑free mixing and printable doses. | — |
| 21 | Synoste Limb lengthening device | $11M | 92 mo ago | 15 | 2012 | Antti Ritvanen Founder & Product Development Director | — | 33 patents Wireless-powered orthopedic bone-lengthening implants and external force generation devices | — |
| 22 | Rappta Therapeutics Provider of a small molecule drug discovery platform for cancer | $11M | 68 mo ago | 11 | 2019 | Sunjeet Sawhney Chief Executive Officer; Board Member | — | 28 patents Small-molecule aromatic PP2A modulators for therapeutic enzyme regulation | — |
| 23 | Woodcast Provider of wooden material for casting and occupational therapy | $11M | 134 mo ago | — | 2008 | Jari Salo Founder | — | — | — |
| 24 | Linio Biotech Developer of medical device for skin and tissue regeneration | $10M | 30 mo ago | 11 | 2017 | Timo Ylikomi Co-Founder & CMO | — | 13 patents Cell‑free adipose‑derived therapeutic preparations for regenerative and cosmetic medicine | — |
| 25 | Bioretec Provider of bioabsorbable, bioactive and drug-releasing surgical implants | $9M | 18 mo ago | 30 | 1985 | Tomi Numminen CEO | WordPressMySQLPHP+17 | 140 patents Biodegradable magnesium alloy orthopedic implants and composite medical device materials | 1 award |
| 26 | Beddit Sleep tracker | $8M | 141 mo ago | 6 | 2007 | — | — | 12 patents Non‑invasive sleep monitoring and quality assessment using physiological sensor data. | — |
| 27 | Neuro Event Labs AI-based seizure monitoring | $7M | 69 mo ago | 35 | 2015 | Kaapo Annala CEO | — | 8 patents EEG-based motor seizure detection and classification algorithms for clinical neuro-monitoring | — |
| 28 | Sooma Oy Non-invasive neuromodulation therapies | $7M | 27 mo ago | 22 | 2013 | — | Cart FunctionalityShopifyShop Pay+28 | 32 patents Non-invasive and implantable transcranial brain stimulation devices and electrodes | — |
| 29 | Vivoxid Develops, manufactures, and markets biomaterial products concentrating on tissue regeneration | $6M | 249 mo ago | — | 2001 | Tomi Numminen Ex-CEO and President | — | 62 patents Biocompatible, resorbable glass‑fiber composite materials for medical implant devices | — |
| 30 | ArcDia Point-of-care diagnostics for acute infectious diseases | $6M | 105 mo ago | 23 | 2008 | — | WordPressMySQLPHP+19 | — | — |
| 31 | Oncos Therapeutics Provider of precision orthopaedics and musculoskeletal oncology solutions | $6M | 193 mo ago | 11 | 2008 | — | WordPressMySQLPHP+23 | 62 patents Patents concentrated in health & consumer products | — |
| 32 | Nukute Provider of cloud-based smart devices to monitor sleep apnea | $5M | 64 mo ago | 24 | 2015 | Tuukka Visuri Co-Founder | — | 3 patents Tracheal airflow monitoring sensors for respiratory diagnostics and ventilation control | — |
| 33 | Pixieray Developer of technology for optical eyeglasses | $4M | 48 mo ago | 33 | 2021 | Rebecca Melakari Co-Founder | — | 134 patents Patents concentrated in computing, sensing & instrumentation | — |
| 34 | Injeq Developer of a medical needle used for lumbar puncture | $4M | 60 mo ago | 22 | 2010 | — | — | 20 patents Integrated biopsy needles with bioimpedance sensing for tissue characterization | — |
| 35 | Veri Provider of a continuous glucose monitor for measuring blood glucose levels | $4M | 60 mo ago | 48 | 2019 | Verneri Jaamuru Co-Founder | PrismicSentryNode.js+29 | — | — |
| 36 | Misvik Biology Provider of precision oncology contract research and toxicology research services | $4M | 39 mo ago | — | 2014 | Juha Rantala Founder & CEO | — | — | — |
| 37 | Arivin Developer of therapeutics for antimicrobial resistance infections | $4M | 9 mo ago | 2 | 2022 | — | — | — | — |
| 38 | MetGen Develops industrial enzymes for Lignocellulosic biomass | $4M | 29 mo ago | 28 | 2008 | Alex Michine Co-Founder & CEO | WordPressMySQLPHP+13 | 123 patents Patents concentrated in chemistry & materials | — |
| 39 | Askel Healthcare Developer of regenerative medicines for cartilage & bone tissue regeneration | $3M | 53 mo ago | 8 | 2017 | Anne Haaparanta Co-Founder & CTO | — | 18 patents Patents concentrated in health & consumer products | — |
| 40 | Biomensio Provider of cloud-based biosensors for diagnostic applications | $3M | 50 mo ago | 18 | 2015 | — | WordPress Block EditorWordPressMySQL+29 | 19 patents Advanced piezoelectric acoustic resonators and fluid/pathogen detection sensor technologies. | — |
| 41 | Grundium Provides portable scanning microscope for medical researcher | $2M | 71 mo ago | 59 | 2015 | Mika Kuisma CEO | BreakdanceWordPressMySQL+28 | 15 patents Microscopy imaging systems: automated image stitching and color calibration technologies. | 1 launch |
| 42 | Finnadvance Developer of microfluidics and microtechnology solutions for drug development | $2M | 50 mo ago | — | 2018 | Prateek Singh Founder & CEO | — | 50 patents Advanced cell culture devices, membrane scaffolds, and microfluidic platforms for biotech research | — |
| 43 | Marginum Developer of surgical devices to detect cancerous tissues | $2M | 9 mo ago | 5 | 2020 | Dmitry Semenov Co-Founder | BootstrapApache HTTP ServerCloudflare+14 | 16 patents Fluorescence-based biomedical sensing and calibration devices for tissue monitoring | — |
| 44 | AfektaTechnologies Mass spectrometry-based metabolomics service provider | $2M | 40 mo ago | 8 | 2017 | Ville Koistinen Co-Founder | — | — | — |
| 45 | Maculaser Developer of laser therapy for the treatment of retinal diseases | $1M | 0 mo ago | 5 | 2018 | Jani Tirronen Co-Founder & CEO | — | 22 patents Ophthalmic temperature monitoring and electroretinogram signal acquisition for retinal therapy | — |
| 46 | GlucoModicum Developer of needle-free glucose monitoring technology for personal health solutions | $1M | 52 mo ago | 37 | 2018 | Johan Bobacka Co-Founder | WordPressApple iCloud MailMicrosoft 365+16 | 34 patents Continuous glucose monitoring and interstitial fluid biosensor technologies | — |
| 47 | Veil Provider of AI and ML based big data analytics and data anonymization solutions | $1M | 45 mo ago | 12 | 2018 | Tuomo Pentikainen CEO | WordPressApple iCloud MailGoogle Workspace+27 | — | — |
| 48 | Solu Cloud based platform for real time genomic pathogen surveillance and epidemiology | $1M | 36 mo ago | — | 2022 | Timo Moilanen Co-Founder | WebflowSentryWistia+12 | — | 1 launch |
| 49 | StemSight Developer of cell therapies for corneal blindness | $590K | 16 mo ago | 8 | 2021 | Heli Skottman Co-Founder | WixSentryBootstrap+9 | 13 patents Stem cell-derived corneal endothelial and limbal cell differentiation for regenerative eye therapies | — |
| 50 | Bioactive Bone Substitutes Developer of bone-graft substitute implants for tissue regeneration and healing | $540K | 27 mo ago | 21 | 2003 | — | WordPressMySQLPHP+10 | 39 patents Formulating bone morphogenetic protein-based osteogenic biomaterials and delivery matrices. | — |
Top 12 Life Sciences companies in Finland
#1
Series B · Helsinki, Uusimaa · founded 2020 · 24 employees$20Mraised▾
Developer of quantum algorithms for chemistry and life science applications. The company develops algorithms that integrate classical and quantum computers. These algorithms address complex problems in quantum chemistry. They also offer solutions for drug discovery and development, targeting rare diseases. The company publishes research in peer-reviewed journals.
- May 2026Series B$21.2M
- Jun 2023Series A$15M
- Feb 2022Seed$5M
#2
Public · Helsinki, Uusimaa · founded 2014 · 3 employees$23Mraised▾
Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas. It provides analysis of digital pathology images for pathologists and researchers. The products are aiforia create, aiforia on-demand, and aiforia cloud.
- Dec 2025Post IPO$4.9M
- Jun 2021Series B$15.4M
- Feb 2021Grant (prize money)$483.6K
- Nov 2019Grant (prize money)$2.3M
#3
Public · Turku, Varsinais-suomi · founded 2007 · 40 employees$160Mraised▾
Faron is a clinical-stage biopharmaceutical company developing drugs for acute organ traumas, vascular damage, and cancer immunotherapy. The pipeline consists of drug candidates (FP-1201-LYO and FP-1305) from two major Faron programmes – Traumakine® and Clevegen®, respectively. The indication of Traumakine (recombinant human IFN beta-1a) is acute respiratory distress syndrome (ARDS) & undergoing phase III clinical trials for the same. In addition, phase II trial is underway for the rupture of abdominal aorta aneurysm (RAAA). The second candidate, Clevegen® is a pre-clinical anti-Clever-1 antibody. It has the ability to switch immune suppression to immune activation in various conditions, This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (TIET). The molecule has the potential indication for oncology, infectious disease, and vaccine development.
- Apr 2025Post IPO$38.1M
- Feb 2025Post IPO$12.5M
- Aug 2024Grant (prize money)$1.5M
- Apr 2024Post IPO$5.2M
#4
Seed · Espoo, Uusimaa · founded 2018 · 5 employees$1.5Mraised▾
Developer of laser therapy for the treatment of retinal diseases. It has developed treatment solutions for common retinal diseases including dry age-related macular degeneration. It helps in temperature control of the macula during non-damaging laser treatments. The treatment solutions mechanisms treat the root causes of AMD that reduce oxidative stress, prevent the aggregation of proteins, improve the transport of nutrients, and enhance RPEs cytoprotective mechanisms.
- Feb 2021Seed$1.5M
#5
Series B · Helsinki, Uusimaa · founded 2013 · 21 employees$29.1Mraised▾
Developer of oncolytic viral immunotherapies for solid tumors. It has patented technology which uses oncolytic viruses to enhance tumor infiltrating lymphocyte therapy and chimeric antigen receptor (CAR) T-cell therapy. The lead product is a cytokine-armed oncolytic adenovirus for platinum-resistant ovarian cancer and also include other therapies for solid tumor.
- May 2025Series B$25M
- Feb 2023Grant (prize money)$2.3M
- Feb 2023Series B$6.3M
- Jul 2022Grant (prize money)$2.2M
#6
Series B · Helsinki, Uusimaa · founded 2016 · 20 employees$25.2Mraised▾
Developer of immunotherapies for cancer and infectious disease. The company uses immunogenic viruses as active carriers of tumor-specific peptides to direct the immune system to specifically target and kill cancer cells. The proprietary PeptiCRAd platform, an oncolytic adenovirus with immunogenic tumor peptides adsorbed onto the negatively charged viral capsid.
- Mar 2025Series B$20.6M
- Apr 2023Grant (prize money)$326.1K
- Nov 2021Series A$12.8M
- Feb 2020Seed$1.2M
#7
Series A · Helsinki, Uusimaa · founded 2021 · 16 employees$11.5Mraised▾
Provider of digital 3D printing solutions for personalized medicine. The company has developed a platform that enables sustainable, quality-controlled production of personalized medicine through its pharmaceutical printing technology. It is a smart drug formulation platform that incorporates cutting-edge technology to redefine the drug compounding process.
- May 2025Conventional Debt$1.1M
- May 2025Series A$7.6M
- Apr 2023Grant (prize money)$2.7M
- Jan 2023Grant (prize money)—
#8
Series A · Helsinki, Uusimaa · founded 2009 · 1 employees$19.5Mraised▾
Aplagon is a Finnish, preclinical stage biotech developing Heparin peptidoglycan mimetics for treating complications of vascular intervention-related blood vessel occlusions. The Heparin peptidoglycan mimetics, are called APACs and are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. APACs, which were discovered by Aplagon scientists, are indicated for the prevention and management of both the short- and long -term complications of vascular intervention-related blood vessel occlusions.
- Feb 2025Series A$7.2M
- Sep 2022Grant (prize money)$2.1M
- 2022Grant (prize money)$10.1M
- Dec 2018Seed—
#9
Seed · Espoo, Uusimaa · founded 2022 · 2 employees$3.5Mraised▾
Developer of therapeutics for antimicrobial resistance infections
- Sep 2025Seed$3.5M
#10
Seed · Kuopio, North Savo · founded 2020 · 5 employees$1.8Mraised▾
Developer of surgical devices to detect cancerous tissues. The company has developed fluorescence-based tissue detection systems that enable safe and efficient monitoring of tumor tissues during cancer surgeries.
- Aug 2025Seed$2.9M
- Nov 2023Seed$1.8M
#11
Public · Tampere, Pirkanmaa · founded 1985 · 30 employees$8.6Mraised▾
Provider of bioabsorbable, bioactive, and drug-releasing surgical implants. The products include bioabsorbable pins, nails, and various types of screws, including interference screws and antibiotic-releasing screws, as well as instruments. Its products, ActivaPin or ActivaNail are used in the fixation of radial head and neck fractures. ActivaScrew is used in the fixation of tibiofibular syndesmosis.CiproScrew is indicated for fixation of bone fractures, osteotomies, arthrodeses, bone grafts, and osteochondral fractures in the presence of appropriate immobilization when infection by a ciprofloxacin-sensitive organisms is a potential risk.
#12
Public · Helsinki, Uusimaa · founded 2008 · 158 employees$47.5Mraised▾
Provider of a platform for the development of nanoparticles. The company uses its multi-patented Controlled Expansion of Supercritical Solutions (CESS) for the development of API nanoparticles directly from the solution. The technology is based on the bottom-up method of recrystallization. It increases the dissolution and bioavailability of nanoparticles and also helps to cross the blood-brain barrier (BBB) for the treatment of CNS disorders such as Alzheimer’s and Parkinson’s disease.
- Feb 2024Grant (prize money)—
- Mar 2021Post IPO$47.5M
Funding & investor landscape
Notable founders
How research on Biotechnology is moving in Finland
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 115 Finland-affiliated papers.
- University of Helsinki28
- University of Turku14
- Helsinki Institute of Physics11
- Helsinki University Hospital11
- Natural Resources Institute Finland11
- Gene3
- Messenger RNA3
- DNA polymerase2
- DNA replication2
- Exon2
- Nutrient4
- Cell3
- Antibody3
- Recombinant DNA3
- Fermentation3
- Production (economics)3
- Gene2
- Functional food2
- Product (mathematics)2
- Sustainability2
Where biotechnology is researched across Finland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.